Amgen Announces Plans to Webcast Selected Management Presentations
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 3, 2005--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that it plans to webcast selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences. Information regarding presentation
times and webcast availability will be noted in advance on Amgen's
Investor Relations Calendar of Events at www.amgen.com. The live
webcasts for these presentations may be accessed via the same link on
the Web site. Information on replays of the webcasts also will be
available on Amgen's Investor Relations Calendar of Events.
Participation in these conferences is subject to change and Amgen
may not webcast all presentations. Therefore, please check the
company's calendar of events prior to each conference.
About Amgen
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
Forward-Looking Statements
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in our Form 10-K for the year ended
December 31, 2004, and in our periodic reports on Form 10-Q and Form
8-K. Amgen is providing this information as of the date of this news
release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. The Company's results may
be affected by our ability to successfully market both new and
existing products domestically and internationally, sales growth of
recently launched products, difficulties or delays in manufacturing
our products, and regulatory developments (domestic or foreign)
involving current and future products and manufacturing facilities. In
addition, sales of our products are affected by reimbursement policies
imposed by first party payors, including governments, private
insurance plans and managed care providers, and may be affected by
domestic and international trends toward managed care and healthcare
cost containment as well as possible US legislation affecting
pharmaceutical pricing and reimbursement. Government regulations and
reimbursement policies may affect the development, usage and pricing
of our products. Furthermore, our research, testing, pricing,
marketing and other operations are subject to extensive regulation by
domestic and foreign government regulatory authorities. We, or others
could identify side effects or manufacturing problems with our
products after they are on the market. In addition, we compete with
other companies with respect to some of our marketed products as well
as for the discovery and development of new products. Discovery or
identification of new product candidates cannot be guaranteed and
movement from concept to product is uncertain; consequently, there can
be no guarantee that any particular product candidate will be
successful and become a commercial product. In addition, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors. Further,
some raw materials, medical devices, and component parts for our
products are supplied by sole first party suppliers.
CONTACT: Amgen, Thousand Oaks
Christine Cassiano, 805-447-4587 (media)
Laura Biswas, 805-447-1060 (investors)
SOURCE: Amgen Inc.